Amit Bar-Or, MD, FRCP, FAAN, FANA
Melissa and Paul Anderson President's Distinguished Professor
Chief, Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine
Director, Center for Neuroinflammation and Neurotherapeutics
Research Scientist, Children's Hospital of Pennsylvania
Staff Neurologist, Perelman School of Medicine, University of Pennsylvania
Department: Neurology
Contact information
Department of Neurology
3400 Spruce Street – 3 Gates Building
Philadelphia, PA 19104
3400 Spruce Street – 3 Gates Building
Philadelphia, PA 19104
Office: 215-662-3606
Fax: 215-662-3362
Fax: 215-662-3362
Graduate Group Affiliations
Publications
Education:
BSc (Biology and Psychology)
McMaster University, 1988.
MD (Medicine)
McGill University, 1993.
BSc (Biology and Psychology)
McMaster University, 1988.
MD (Medicine)
McGill University, 1993.
Post-Graduate Training
Intern in Medicine, Massachusetts General Hospital (MGH), Harvard Medical School (HMS), 1993-1994.
Fellow in Neurology, Massachusetts General Hospital (MGH), Harvard Medical School (HMS), 1994-1997.
Postdoctoral Research Fellow, Cellular and Molecular Immunology, Center for Neurologic Disease, Harvard Medical School, 1997-2000.
Clinical Fellow in Neurology, Brigham and Women's Hospital (BWH), 1997-2000.
Postdoctoral Research Fellow, Clinical Investigator Training Program, Harvard Medical School (HMS), Massachusetts Institute of Technology, 1997-1998.
Intern in Medicine, Massachusetts General Hospital (MGH), Harvard Medical School (HMS), 1993-1994.
Fellow in Neurology, Massachusetts General Hospital (MGH), Harvard Medical School (HMS), 1994-1997.
Postdoctoral Research Fellow, Cellular and Molecular Immunology, Center for Neurologic Disease, Harvard Medical School, 1997-2000.
Clinical Fellow in Neurology, Brigham and Women's Hospital (BWH), 1997-2000.
Postdoctoral Research Fellow, Clinical Investigator Training Program, Harvard Medical School (HMS), Massachusetts Institute of Technology, 1997-1998.
Certifications
Medical Council of Canada, 1994.
American Academy of Neurology (AAN), 1997.
American Neurological Association (ANA), 1997.
American Board of Psychiatry and Neurology, 1998.
Royal College of Physicians of Canada (FRCPC), 1998.
Federation des Médecins du Québec (FMQ), 2000.
Federation des Médecins Specialists du Québec (FMSQ), 2000.
Permanent linkMedical Council of Canada, 1994.
American Academy of Neurology (AAN), 1997.
American Neurological Association (ANA), 1997.
American Board of Psychiatry and Neurology, 1998.
Royal College of Physicians of Canada (FRCPC), 1998.
Federation des Médecins du Québec (FMQ), 2000.
Federation des Médecins Specialists du Québec (FMSQ), 2000.
Selected Publications
Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J: Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm 4(3), Mar 2017.Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; : Monophasic demyelination reduces brain growth in children Neurology April 2017.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L: OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 376(3): 221-234, Jan 2017.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky J: ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J. 376(3): 221-234, Jan 2017.
Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A*: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. J Immunol. 198(2): 691--698, Jan 2017.
Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A: Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Transl Med. pii: sctm.2015-0243(11), Jul 2016.
Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore C, Michel L, Althekair F, Rajasekharan S, Gommerman J, Prat A, Fillatreau S and Bar-Or A on behalf of the 'Canadian B cells in MS Team': Proinflammatory GM-CSF producing B cells: implication in multiple sclerosis and B cell depletion therapy. Sci Transl Med 7(310): 166, Oct 2015.
Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network: Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler 22(3): 385-8, Mar 2016.
Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F: Randomized study of teriflunomide effects on immune responses to neo-antigen and recall antigens. Neurol Neuroimmunol Neuroinflamm. 2(2): e70, Feb 2015.
Moore CS, Cui QL, Warsi NM, Durafourt BA, Zorko N, Owen DR, Antel JP, and Bar-Or A: Direct and Indirect Effects of Immune and Central Nervous System–Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation. J Immunol 194(2): 761-72, Jan 2015.